Effects of of rosuvastatin short-term intensive therapy on cardiac function and inflammatory response of patients with acute coronary syndrome after PCI

doi:10.3969/j.issn.1002-7386.2018.13.012

Abstract：Objective To explore the effects of rosuvastatin short term intensive therapy on cardiac function and inflammatory response of patients with acute coronary syndrome ( ACS) after percutaneous coronary intervention ( PCI). Methods A total of 166 patients with ACS who were treated by PCI in our hospital from January 2014 to January 2015 were divided into control group (n=83) and research group (n=83) according to random number table. After PCI,the patients in control group were treated by routine treatment,howeve,the patients in research group, on the basis of control group, were treated by oral rosuvastatin tablets,with a treatment couse of one month for both groups. The cardiac function and structure of patients were detected before and after treatment respectively, and the levels of creatine kinase isoenzyme ( CK-MB) and myocardial troponin (cTnI) in blood were detected by full automatic biochemical analyzer. At the same time, inflammatory response related indexes were tested by enzyme-linked immunosorbent assay. In addition, the incidence rates of adverse reactions and cardiac adverse events were statistically analyzed. Results After treatment, the levels of CK-MB, cTnI, left ventricular ejection fraction (LVEF), early ventricular diastolic peak velocity/late ventricular diastolic peak velocity of blood flow to the left atrioventricular valve ( E/A) values were significantly increased in both groups. Moreover the left ventricular end systolic inner diameter ( LVSD ) and left ventricular end diastolic inner diameter ( LVDD ) in both groups were significantly lower than those before treatment. As compared with those before treatment, the levels of high-sensitivity C-reactive protein (hs-CRP), brain natriuretic peptide (BNP), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) were significantly decreased after treatment in both groups,moreover the levels of inflammatory indexes in research group were significantly lower than those in control group(P＜0. 05). In addition the incidence rate of adverse reactions in control group and research group was 7. 22% (6/83) and 6. 02% (5/83) respectively, and the incidence rate of cardiovascular events in thetwogroupswas16.87% (14/83) and14.46% (12/83),respectively,however,therewerenosignificantdifferences between two groups (P＞0. 05). Conclusion Rosuvastatin short-term intensive therapy can effectively improve the heart function and inflammation reaction of patients with ACS after PCI, with higher safety,thus, which is worth using widely in clinical practice.